Global Nervous System Markers Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Nervous System Markers Market Insights, Forecast to 2034
A major percentage of world population is affected by neurological disorders, this in turn is causing major disabilities globally. Due to the high incidence of neurological disorders, there is the need for biomarkers as biomarkers measure biological states and are used for indication of both pathogenic as well as normal biological process in terms of therapeutic intervention. Biomarkers can also be utilized in combination for accessing the state of the disease of an individual.
Global Nervous System Markers market is expected to reach to US$ 566.9 million in 2024, with a positive growth of %, compared with US$ 543.6 million in 2022. Backed with the increasing demand from downstream industries, Nervous System Markers industry is evaluated to reach US$ 808.7 million in 2029. The CAGR will be 6.1% during 2024 to 2029.
According to the "Global Use of Medicines 2024" released by the IQVIA Institute, the global drug expenditure in 2022 will be approximately US$1.48 trillion (excluding costs related to COVID vaccines and therapies), and it is predicted that it will grow at a rate of 3%-6% in the next few years. In terms of regional development trends, high-income countries such as Western Europe, North America, and Japan are expected to experience slower growth in the next few years due to already high per capita usage, while growth markets such as Asia, Latin America, and Eastern Europe are expected to grow strongly. In terms of drug expenditure, China's drug expenditure in 2022 will be about 166 billion US dollars. It is expected that the expenditure on medicines will only increase in the next few yearsFrom the perspective of demand, the trend of population aging, the increase of residents’ wealth and the improvement of health awareness will drive the demand for medicines; from the perspective of national strategy, in 2016 , the State Council issued the "Healthy China 2030" Planning Outline, and "Healthy China" has risen to a national strategy; from the perspective of industry policy, it has experienced the uncertainty brought about by the initial stage of medical reform, the implementation of the centralized procurement policy and the expansion of the drug reimbursement catalog The update will gradually achieve a dynamic balance of multiple goals such as promoting innovation, stabilizing supply, and reducing the burden on the masses.
Report Covers
This report presents an overview of global Nervous System Markers market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Nervous System Markers market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
Athena Diagnostics
Myriad RBM
QIAGEN
Thermo Fisher Scientific
Segment by Type
Imaging Biomarkers
Metabolomics Biomarkers
Proteomic Biomarkers
Genomics Biomarkers
Spinal Muscular Atrophy (SMA)
Multiple Sclerosis
Depression
Schizophrenia
Huntington's Disease
Parkinson's Disease
Alzheimer's Disease
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Nervous System Markers plant distribution, commercial date of Nervous System Markers, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Nervous System Markers introduction, etc. Nervous System Markers Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Nervous System Markers
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Global Nervous System Markers market is expected to reach to US$ 566.9 million in 2024, with a positive growth of %, compared with US$ 543.6 million in 2022. Backed with the increasing demand from downstream industries, Nervous System Markers industry is evaluated to reach US$ 808.7 million in 2029. The CAGR will be 6.1% during 2024 to 2029.
According to the "Global Use of Medicines 2024" released by the IQVIA Institute, the global drug expenditure in 2022 will be approximately US$1.48 trillion (excluding costs related to COVID vaccines and therapies), and it is predicted that it will grow at a rate of 3%-6% in the next few years. In terms of regional development trends, high-income countries such as Western Europe, North America, and Japan are expected to experience slower growth in the next few years due to already high per capita usage, while growth markets such as Asia, Latin America, and Eastern Europe are expected to grow strongly. In terms of drug expenditure, China's drug expenditure in 2022 will be about 166 billion US dollars. It is expected that the expenditure on medicines will only increase in the next few yearsFrom the perspective of demand, the trend of population aging, the increase of residents’ wealth and the improvement of health awareness will drive the demand for medicines; from the perspective of national strategy, in 2016 , the State Council issued the "Healthy China 2030" Planning Outline, and "Healthy China" has risen to a national strategy; from the perspective of industry policy, it has experienced the uncertainty brought about by the initial stage of medical reform, the implementation of the centralized procurement policy and the expansion of the drug reimbursement catalog The update will gradually achieve a dynamic balance of multiple goals such as promoting innovation, stabilizing supply, and reducing the burden on the masses.
Report Covers
This report presents an overview of global Nervous System Markers market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Nervous System Markers market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Athena Diagnostics
Myriad RBM
QIAGEN
Thermo Fisher Scientific
Segment by Type
Imaging Biomarkers
Metabolomics Biomarkers
Proteomic Biomarkers
Genomics Biomarkers
Segment by Application
Spinal Muscular Atrophy (SMA)
Multiple Sclerosis
Depression
Schizophrenia
Huntington's Disease
Parkinson's Disease
Alzheimer's Disease
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Nervous System Markers plant distribution, commercial date of Nervous System Markers, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Nervous System Markers introduction, etc. Nervous System Markers Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Nervous System Markers
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices